Avalo Therapeutics, Inc.
AVTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $178 | $54 | $84 | $78 |
| - Cash | $27 | $42 | $125 | $135 |
| + Debt | $0 | $3 | $1 | $1 |
| Enterprise Value | $151 | $14 | -$40 | -$56 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | -100% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | 54.7% |
| EBITDA | -$31 | -$19 | -$15 | -$13 |
| % Margin | – | – | – | -6,897.4% |
| Net Income | -$31 | -$21 | -$13 | -$35 |
| % Margin | – | – | – | -18,405.7% |
| EPS Diluted | -2.19 | -1.92 | -1.25 | 10.47 |
| % Growth | -14.1% | -53.6% | -111.9% | – |
| Operating Cash Flow | -$16 | -$11 | -$9 | -$15 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$16 | -$11 | -$9 | -$15 |